Stockscreener 앱 받기
29.52
0.54%
0.16
시장 영업 전:
29.50
-0.02
-0.07%
전일 마감가:
$29.36
열려 있는:
$29.07
하루 거래량:
1.17M
Relative Volume:
0.65
시가총액:
$2.84B
수익:
$522.75M
순이익/손실:
$-558.99M
주가수익비율:
-4.5626
EPS:
-6.47
순현금흐름:
$-439.53M
1주 성능:
+1.76%
1개월 성능:
+11.86%
6개월 성능:
-30.69%
1년 성능:
-48.26%
1일 변동 폭
$28.85
$29.62
1주일 범위
$28.85
$30.10
52주 변동 폭
$25.81
$60.37
울트라제닉스 파마슈티컬 Stock (RARE) Company Profile
명칭
Ultragenyx Pharmaceutical Inc
전화
415-483-8800
주소
60 LEVERONI COURT, NOVATO, CA
RARE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
29.52 | 2.86B | 522.75M | -558.99M | -439.53M | -6.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.46 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.16 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
467.55 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
663.73 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.97 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
울트라제닉스 파마슈티컬 Stock (RARE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-28 | 재개 | H.C. Wainwright | Buy |
| 2025-05-28 | 개시 | William Blair | Outperform |
| 2024-06-06 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-04-22 | 개시 | RBC Capital Mkts | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-06-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-04-26 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-12-30 | 재개 | H.C. Wainwright | Buy |
| 2022-11-03 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-08-01 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-03-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-09-30 | 개시 | H.C. Wainwright | Buy |
| 2021-08-19 | 개시 | UBS | Sell |
| 2021-07-15 | 개시 | Guggenheim | Neutral |
| 2021-06-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-05-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-05-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-03-02 | 재개 | Stifel | Buy |
| 2021-02-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-11-24 | 재개 | Evercore ISI | In-line |
| 2020-11-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2019-08-02 | 재개 | Wedbush | Outperform |
| 2019-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2018-09-10 | 개시 | Morgan Stanley | Equal-Weight |
| 2018-06-21 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-05-10 | 개시 | Goldman | Neutral |
| 2018-04-18 | 업그레이드 | SunTrust | Hold → Buy |
| 2018-03-22 | 재개 | Piper Jaffray | Overweight |
| 2018-02-21 | 재확인 | Stifel | Buy |
| 2018-01-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-01-18 | 개시 | Credit Suisse | Outperform |
| 2017-12-05 | 재확인 | Barclays | Equal Weight |
| 2017-12-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-09-14 | 업그레이드 | Wedbush | Neutral → Outperform |
모두보기
울트라제닉스 파마슈티컬 주식(RARE)의 최신 뉴스
Will Ultragenyx Pharmaceutical Inc. Recover After Recent Decline2025 Fundamental Recap & Daily Profit Maximizing Trade Tips - newsyoung.net
Ultragenyx starts FDA marketing application process for its gene therapy - MSN
Machine Learning Models Forecast Ultragenyx Pharmaceutical Inc. UptickBear Alert & Reliable Breakout Forecasts - kangso.co.kr
Ultragenyx Initiates Rolling Submission of Biologics License Application to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia - MarketScreener
Ultragenyx Initiates Rolling BLA Submission for DTX401 Gene Therapy - AInvest
Ultragenyx Initiates BLA Submission for DTX401 Gene Therapy in GSDIa Treatment. - AInvest
Ultragenyx initiates rolling submission of BLA to U.S. FDA for DTX401 - TipRanks
Chartists See Breakout Potential in Ultragenyx Pharmaceutical Inc.July 2025 Weekly Recap & AI Enhanced Trade Execution Alerts - 선데이타임즈
Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa) - GlobeNewswire
Ultragenyx Initiates Submission Of BLA To The U.S. FDA For DTX401 AAV Gene Therapy - TradingView
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt - 富途牛牛
Rett Syndrome Pipeline 2025: MOA, ROA, and Clinical Trial - openPR.com
Ultragenyx Begins FDA Marketing Application for DTX401 Gene Therapy for GSD Type Ia - AInvest
Ultragenyx Begins FDA Application for DTX401 Gene Therapy - TipRanks
Rett Syndrome Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Neuren Pharma, Anavex Life Sciences, Edison Pharma, Novartis, Ultragenyx Pharma, GW Pharma, Q-State - Barchart.com
Ultragenyx initiates rolling BLA submission for GSDIa gene therapy By Investing.com - Investing.com Nigeria
Ultragenyx initiates rolling BLA submission for GSDIa gene therapy - Investing.com
Ultragenyx Pharmaceutical Begins Biologics License Application for Glycogen Storage Disease Gene Therapy - MarketScreener
Ultragenyx Initiates BLA Submission for DTX401 Gene Therapy in GSDIa. - AInvest
Ultragenyx Initiates Rolling Submission of Biologics - GlobeNewswire
Ultragenyx Initiates Rolling Submission of Biologics License Application for DTX401 AAV Gene Therapy to Treat GSDIa - AInvest
64% Treatment Success: Ultragenyx's Gene Therapy DTX401 Advances FDA Review for Rare Disease GSDIa - Stock Titan
RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome - MSN
Pomerantz LLP investigates Ultragenyx Pharmaceutical securities fraud claims. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - GlobeNewswire Inc.
Will earnings trigger a reversal in Ultragenyx Pharmaceutical Inc.Trade Risk Report & Free High Return Stock Watch Alerts - Newser
Why Ultragenyx (RARE) Is Up 7.8% After Reporting Narrowed Losses and Higher Q2 Revenue - simplywall.st
Will Ultragenyx Pharmaceutical Inc. bounce back from current supportJuly 2025 Market Mood & Accurate Intraday Trade Tips - Newser
How high can Ultragenyx Pharmaceutical Inc. stock goEarnings Overview Report & Reliable Intraday Trade Plans - Newser
Price Clustering Detected in Ultragenyx Pharmaceutical Inc. StockWeekly Trade Summary & Safe Investment Capital Preservation Plans - sundaytimes.kr
Ultragenyx Pharmaceutical Inc. Shows Support at Fibonacci LevelWeekly Risk Summary & Community Verified Watchlist Alerts - metal.it
Navigating Legal Storms in Biotech: The Ultragenyx Case and Investor Caution - AInvest
Ultragenyx Pharmaceutical faces securities fraud investigation. - AInvest
News impact scoring models applied to Ultragenyx Pharmaceutical Inc.Trade Entry Summary & Verified Short-Term Plans - Newser
How sentiment analysis helps forecast Ultragenyx Pharmaceutical Inc.2025 Risk Factors & Safe Capital Allocation Plans - Newser
Long term hold vs stop loss in Ultragenyx Pharmaceutical Inc.July 2025 Trends & Fast Gaining Stock Strategy Reports - Newser
Is Ultragenyx Pharmaceutical Inc. the Top Chart Pick This WeekMarket Volume Summary & Free Weekly Watchlist of Top Performers - 선데이타임즈
What are analysts’ price targets for Ultragenyx Pharmaceutical Inc.July 2025 Action & Verified Chart Pattern Trade Signals - sundaytimes.kr
RSI Reset May Fuel Rebound in Ultragenyx Pharmaceutical Inc.Wall Street Watch & Free AI Powered Buy and Sell Recommendations - newsyoung.net
Ultragenyx Investors Investigated for Securities Fraud and Unlawful Practices. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx - Bluefield Daily Telegraph
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q2 2025 Earnings Call Transcript - MSN
Ultragenyx Says CRL Discussions ‘Productive’ Despite US FDA Leadership Upheaval - insights.citeline.com
Mereo BioPharma Group (MREO) Announced Progress in the Phase 3 Orbit Study Testing UX143 - MSN
Sarepta’s Woes Put the Stalwart AAV Under a Harsh Light - BioSpace
Cantor Fitzgerald Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $105.00 - MarketBeat
Reversal indicators forming on Ultragenyx Pharmaceutical Inc. stockWeekly Growth Portfolio Performance Summary - Newser
Technical Charts Suggest Momentum Shift in Ultragenyx Pharmaceutical Inc.Potential Breakout Stock List Published This Week - beatles.ru
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN
How Ultragenyx Pharmaceutical Inc. stock performs during market volatilityFree Triple Digit Return Stock Predictions - Newser
울트라제닉스 파마슈티컬 (RARE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.55%
0.38%
자본화:
|
볼륨(24시간):